TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07165028: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 4500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,654,544

Rescue Site Savings

+$7,024,456

Unlock Full NCT07165028 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07165028 Rescue Dossier →